Evidence map›Paper›PMID 21536162›Full record

ReviewThe Psychiatric clinics of North America2011

Late-life depression: evidence-based treatment and promising new directions for research and clinical practice.

Carmen Andreescu, Charles F Reynolds

Registry-linked trialAbstract readReview
In one paragraph

Review in The Psychiatric clinics of North America, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03128021 (Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response), which is not on this map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03128021 phase4completednot on this mapstarted 2017, after this paper: background citation

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

TypeinterventionalSponsorHoward AizensteinRan2017 to 2023Enrolled57ConditionsMajor Depressive DisorderArmsEscitalopram Pill, Placebo, Levomilnacipran Pill
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Perspectives on the Management of Vascular Depression.The American journal of psychiatry · 2018
    Review
  12. Article
  13. Directions for Effectiveness Research to Improve Health Services for Late-Life Depression in the United States.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2016
    Review
  14. Article
  15. Observational
  16. Review
  17. Article
  18. The age-by-disease interaction hypothesis of late-life depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2013
    Review
  19. Article
  20. Treatment of depression in older adults.Current psychiatry reports · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carmen AndreescuDepartment of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh, 3811 O'Hara Street, 247 Sterling Plaza, Pittsburgh, PA 15213, USA.
Charles F Reynolds

Funding

Research Network Development Core (pages 329-374)P30MH071944 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REYNOLDS, CHARLES F. · 2005 to 2009
$6.7M
1/3-Incomplete Response in Late-Life Depression: Getting to RemissionR01MH083660 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REYNOLDS, CHARLES F. · 2009 to 2013
$2.7M
Functional and Structural Neuroanatomy in Late-Life Generalized Anxiety DisorderK23MH086686 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANDREESCU, CARMEN · 2010 to 2014
$841k
NIMH NIH HHS K23 MH 086686NIMH NIH HHS K23 MH086686NIMH NIH HHS P30 MH071944NIMH NIH HHS P30 MH71944NIMH NIH HHS R01 MH 083660NIMH NIH HHS R01 MH083660
6 · The paper itself

Abstract

As the population ages, successive cohorts of older adults will experience depressive disorders. Late-life depression (LLD) carries additional risk for suicide, medical comorbidity, disability, and family caregiving burden. Although response and remission rates to pharmacotherapy and electroconvulsive therapy are comparable with those in midlife depression, relapse rates are higher, underscoring the challenge to achieve and maintain wellness. This article reviews the evidence base for LLD treatment options and provides an analysis of treatment options for difficult-to-treat LLD variants (eg, psychotic depression, vascular depression). Treatment algorithms are also reviewed based on predictors of response and promising novel treatment options.

Indexed as

Drug TherapyElectroconvulsive TherapyAgedAged, 80 and overAgingDepressive DisorderEvidence-Based MedicineHumansPractice Guidelines as TopicRisk FactorsSeverity of Illness IndexSuicideTreatment Outcome

Identifiers

PMID21536162
PMCPMC8442985

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.